Barclays PLC Grows Position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

Barclays PLC boosted its holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 128.2% in the 3rd quarter, HoldingsChannel reports. The fund owned 154,297 shares of the biopharmaceutical company’s stock after acquiring an additional 86,677 shares during the quarter. Barclays PLC’s holdings in Vanda Pharmaceuticals were worth $722,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of VNDA. ORG Wealth Partners LLC purchased a new position in shares of Vanda Pharmaceuticals in the third quarter valued at $40,000. China Universal Asset Management Co. Ltd. increased its position in shares of Vanda Pharmaceuticals by 64.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 11,211 shares of the biopharmaceutical company’s stock valued at $53,000 after buying an additional 4,374 shares in the last quarter. XTX Topco Ltd purchased a new position in shares of Vanda Pharmaceuticals in the second quarter valued at $75,000. Intech Investment Management LLC purchased a new position in shares of Vanda Pharmaceuticals in the third quarter valued at $84,000. Finally, SG Americas Securities LLC increased its position in shares of Vanda Pharmaceuticals by 88.5% in the third quarter. SG Americas Securities LLC now owns 20,402 shares of the biopharmaceutical company’s stock valued at $96,000 after buying an additional 9,580 shares in the last quarter. Hedge funds and other institutional investors own 88.14% of the company’s stock.

Insider Buying and Selling

In related news, Director Stephen Ray Mitchell sold 5,000 shares of the stock in a transaction dated Thursday, November 14th. The stock was sold at an average price of $5.17, for a total transaction of $25,850.00. Following the transaction, the director now directly owns 44,857 shares in the company, valued at approximately $231,910.69. This represents a 10.03 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 8.90% of the stock is owned by company insiders.

Vanda Pharmaceuticals Price Performance

Vanda Pharmaceuticals stock opened at $4.45 on Thursday. The firm’s 50-day moving average is $4.86 and its two-hundred day moving average is $5.05. The stock has a market capitalization of $259.47 million, a P/E ratio of -15.89 and a beta of 0.77. Vanda Pharmaceuticals Inc. has a 12-month low of $3.46 and a 12-month high of $6.75.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on VNDA shares. HC Wainwright restated a “buy” rating and issued a $18.00 price target on shares of Vanda Pharmaceuticals in a research report on Monday, December 23rd. StockNews.com started coverage on Vanda Pharmaceuticals in a research report on Sunday. They issued a “hold” rating for the company.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.